Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Gait Speed vs. VES-13: A Pilot Study Comparing Screening Tools to Determine the Need for a Comprehensive Geriatric Assessment in Senior Women with Breast Cancer.

Hollenberg DC, Menjak IB, Mehta R, Bristow B, Trudeau ME, Gibson L, Neve M, Norris M, Pasetka M, Rice K, McCullock F, Wright FC, Szumacher E.

J Med Imaging Radiat Sci. 2019 Dec;50(4):551-556. doi: 10.1016/j.jmir.2019.06.053. Epub 2019 Nov 25.

PMID:
31780434
2.

Ambulatory Toxicity Management (AToM) in patients receiving adjuvant or neo-adjuvant chemotherapy for early stage breast cancer - a pragmatic cluster randomized trial protocol.

Krzyzanowska MK, Julian JA, Powis M, Howell D, Earle CC, Enright KA, Mittmann N, Trudeau ME, Grunfeld E.

BMC Cancer. 2019 Sep 5;19(1):884. doi: 10.1186/s12885-019-6099-x.

3.

The impact of pricing strategy on the costs of oral anti-cancer drugs.

Truong J, Chan KKW, Mai H, Chambers A, Sabharwal M, Trudeau ME, Cheung MC.

Cancer Med. 2019 Jul;8(8):3770-3781. doi: 10.1002/cam4.2269. Epub 2019 May 27.

4.

Conditional approval of cancer drugs in Canada: accountability and impact on public funding.

Andersen SK, Penner N, Chambers A, Trudeau ME, Chan KKW, Cheung MC.

Curr Oncol. 2019 Feb;26(1):e100-e105. doi: 10.3747/co.26.4397. Epub 2019 Feb 1.

5.

Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update.

Denduluri N, Chavez-MacGregor M, Telli ML, Eisen A, Graff SL, Hassett MJ, Holloway JN, Hurria A, King TA, Lyman GH, Partridge AH, Somerfield MR, Trudeau ME, Wolff AC, Giordano SH.

J Clin Oncol. 2018 Aug 10;36(23):2433-2443. doi: 10.1200/JCO.2018.78.8604. Epub 2018 May 22.

PMID:
29787356
6.

Factors associated with imaging in patients with early breast cancer after initial treatment.

Enright K, Desai T, Sutradhar R, Gonzalez A, Powis M, Taback N, Booth CM, Trudeau ME, Krzyzanowska MK.

Curr Oncol. 2018 Apr;25(2):126-132. doi: 10.3747/co.25.3838. Epub 2018 Apr 30.

7.

Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.

Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O'Shaughnessy J, Gradishar W, Schmid P, Winer E, Kelly C, Nanda R, Gucalp A, Awada A, Garcia-Estevez L, Trudeau ME, Steinberg J, Uppal H, Tudor IC, Peterson A, Cortes J.

J Clin Oncol. 2018 Mar 20;36(9):884-890. doi: 10.1200/JCO.2016.71.3495. Epub 2018 Jan 26.

8.

Setting Quality Improvement Priorities for Women Receiving Systemic Therapy for Early-Stage Breast Cancer by Using Population-Level Administrative Data.

Enright KA, Taback N, Powis ML, Gonzalez A, Yun L, Sutradhar R, Trudeau ME, Booth CM, Krzyzanowska MK.

J Clin Oncol. 2017 Oct 1;35(28):3207-3214. doi: 10.1200/JCO.2016.70.7950. Epub 2017 Jul 6.

PMID:
28682683
9.

The impact of cancer drug wastage on economic evaluations.

Truong J, Cheung MC, Mai H, Letargo J, Chambers A, Sabharwal M, Trudeau ME, Chan KKW.

Cancer. 2017 Sep 15;123(18):3583-3590. doi: 10.1002/cncr.30807. Epub 2017 Jun 22.

10.

Correction: Quantitative ultrasound assessment of breast tumor response to chemotherapy using a multi-parameter approach.

Tadayyon H, Sannachi L, Gangeh M, Sadeghi-Naini A, Tran W, Trudeau ME, Pritchard K, Ghandi S, Verma S, Czarnota GJ.

Oncotarget. 2017 May 23;8(21):35481. doi: 10.18632/oncotarget.18068. No abstract available.

11.

Reply to L. Del Mastro and A. Prat.

Denduluri N, Somerfield MR, Eisen A, Holloway JN, Hurria A, King TA, Lyman GH, Partridge AH, Telli ML, Trudeau ME, Wolff AC.

J Clin Oncol. 2017 Apr 1;35(10):1139. doi: 10.1200/JCO.2016.70.9758. Epub 2017 Jan 17. No abstract available.

PMID:
28095161
12.

Association of hospital and physician case volumes with cardiac monitoring and cardiotoxicity during adjuvant trastuzumab treatment for breast cancer: a retrospective cohort study.

Chin-Yee NJ, Yan AT, Kumachev A, Ko D, Earle C, Tomlinson G, Trudeau ME, Krahn M, Krzyzanowska M, Pal R, Brezden-Masley C, Gavura S, Lien K, Chan K.

CMAJ Open. 2016 Feb 18;4(1):E66-72. doi: 10.9778/cmajo.20150033. eCollection 2016 Jan-Mar.

13.

Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: a population-based study.

Gong IY, Verma S, Yan AT, Ko DT, Earle CC, Tomlinson GA, Trudeau ME, Krahn MD, Krzyzanowska MK, Brezden-Masley CB, Gavura S, Peacock S, Chan KK.

Breast Cancer Res Treat. 2016 Jun;157(3):535-44. doi: 10.1007/s10549-016-3823-y. Epub 2016 Jun 6.

PMID:
27271767
14.

Quantitative ultrasound assessment of breast tumor response to chemotherapy using a multi-parameter approach.

Tadayyon H, Sannachi L, Gangeh M, Sadeghi-Naini A, Tran W, Trudeau ME, Pritchard K, Ghandi S, Verma S, Czarnota GJ.

Oncotarget. 2016 Jul 19;7(29):45094-45111. doi: 10.18632/oncotarget.8862. Erratum in: Oncotarget. 2017 May 23;8(21):35481.

15.

Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline.

Denduluri N, Somerfield MR, Eisen A, Holloway JN, Hurria A, King TA, Lyman GH, Partridge AH, Telli ML, Trudeau ME, Wolff AC.

J Clin Oncol. 2016 Jul 10;34(20):2416-27. doi: 10.1200/JCO.2016.67.0182. Epub 2016 Apr 18. Erratum in: J Clin Oncol. 2017 Jan 10;35(2):263. Erratum in: J Clin Oncol. 2017 Apr 1;35(10):1140.

PMID:
27091714
16.

A population-based study of the epidemiology of pancreatic cancer: a brief report.

Raju RS, Coburn N, Liu N, Porter JM, Seung SJ, Cheung MC, Goyert N, Leighl NB, Hoch JS, Trudeau ME, Evans WK, Dainty KN, Earle CC, Mittmann N.

Curr Oncol. 2015 Dec;22(6):e478-84. doi: 10.3747/co.22.2653.

17.

Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis.

Truong J, Lee EK, Trudeau ME, Chan KK.

Ann Oncol. 2016 Apr;27(4):608-18. doi: 10.1093/annonc/mdv619. Epub 2015 Dec 27. Review.

PMID:
26712901
18.

Associations among socioeconomic status, patterns of care and outcomes in breast cancer patients in a universal health care system: Ontario's experience.

Kumachev A, Trudeau ME, Chan KK.

Cancer. 2016 Mar 15;122(6):893-8. doi: 10.1002/cncr.29838. Epub 2015 Dec 22.

19.

Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario.

Levine MN, Julian JA, Bedard PL, Eisen A, Trudeau ME, Higgins B, Bordeleau L, Pritchard KI.

J Clin Oncol. 2016 Apr 1;34(10):1065-71. doi: 10.1200/JCO.2015.62.8503. Epub 2015 Nov 23.

PMID:
26598746
20.

A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22.

Trudeau ME, Chapman JA, Guo B, Clemons MJ, Dent RA, Jong RA, Kahn HJ, Pritchard KI, Han L, O'Brien P, Shepherd LE, Parissenti AM.

Springerplus. 2015 Oct 21;4:631. doi: 10.1186/s40064-015-1392-x. eCollection 2015.

21.

The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study.

Goldhar HA, Yan AT, Ko DT, Earle CC, Tomlinson GA, Trudeau ME, Krahn MD, Krzyzanowska MK, Pal RS, Brezden-Masley C, Gavura S, Lien K, Chan KK.

J Natl Cancer Inst. 2015 Oct 16;108(1). pii: djv301. doi: 10.1093/jnci/djv301. Print 2016 Jan.

PMID:
26476433
22.

Tumor RNA disruption predicts survival benefit from breast cancer chemotherapy.

Parissenti AM, Guo B, Pritzker LB, Pritzker KP, Wang X, Zhu M, Shepherd LE, Trudeau ME.

Breast Cancer Res Treat. 2015 Aug;153(1):135-44. doi: 10.1007/s10549-015-3498-9. Epub 2015 Jul 25.

PMID:
26208483
23.

Economic evaluation of hormonal therapies for postmenopausal women with estrogen receptor-positive early breast cancer in Canada.

Djalalov S, Beca J, Amir E, Krahn M, Trudeau ME, Hoch JS.

Curr Oncol. 2015 Apr;22(2):84-96. doi: 10.3747/co.22.2120.

24.

Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.

Freedman OC, Fletcher GG, Gandhi S, Mates M, Dent SF, Trudeau ME, Eisen A.

Curr Oncol. 2015 Mar;22(Suppl 1):S95-S113. doi: 10.3747/co.22.2326. Review.

25.

Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.

Gandhi S, Fletcher GG, Eisen A, Mates M, Freedman OC, Dent SF, Trudeau ME.

Curr Oncol. 2015 Mar;22(Suppl 1):S82-94. doi: 10.3747/co.22.2321. Review.

26.

Outcome of patients with pregnancy during or after breast cancer: a review of the recent literature.

Raphael J, Trudeau ME, Chan K.

Curr Oncol. 2015 Mar;22(Suppl 1):S8-S18. doi: 10.3747/co.22.2338. Review.

27.

The best available evidence ... all in one place.

Trudeau ME.

Curr Oncol. 2015 Mar;22(Suppl 1):S7. doi: 10.3747/co.22.2617. No abstract available.

28.

Optimal systemic therapy for early breast cancer in women: a clinical practice guideline.

Eisen A, Fletcher GG, Gandhi S, Mates M, Freedman OC, Dent SF, Trudeau ME; members of the Early Breast Cancer Systemic Therapy Consensus Panel.

Curr Oncol. 2015 Mar;22(Suppl 1):S67-81. doi: 10.3747/co.22.2320.

29.

Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.

Mates M, Fletcher GG, Freedman OC, Eisen A, Gandhi S, Trudeau ME, Dent SF.

Curr Oncol. 2015 Mar;22(Suppl 1):S114-22. doi: 10.3747/co.22.2322. Review.

30.

Cost-effectiveness of prophylactic granulocyte colony-stimulating factor for febrile neutropenia in breast cancer patients receiving FEC-D.

Lee EK, Wong WW, Trudeau ME, Chan KK.

Breast Cancer Res Treat. 2015 Feb;150(1):169-80. doi: 10.1007/s10549-015-3309-3. Epub 2015 Feb 19.

PMID:
25694355
31.

End-of-life home care utilization and costs in patients with advanced colorectal cancer.

Mittmann N, Liu N, Porter JM, Isogai PK, Saskin R, Cheung MC, Leighl NB, Hoch JS, Trudeau ME, Evans WK, Dainty KN, Earle CC.

J Community Support Oncol. 2014 Mar;12(3):92-8.

PMID:
24971414
32.

Patients' perceptions of gene expression profiling in breast cancer treatment decisions.

Bombard Y, Rozmovits L, Trudeau ME, Leighl NB, Deal K, Marshall DA.

Curr Oncol. 2014 Apr;21(2):e203-11. doi: 10.3747/co.21.1524.

33.

Population-based home care services in breast cancer: utilization and costs.

Mittmann N, Isogai PK, Saskin R, Liu N, Porter JM, Cheung MC, Leighl NB, Hoch JS, Trudeau ME, Evans WK, Dainty KN, Earle CC.

Curr Oncol. 2012 Dec;19(6):e383-91. doi: 10.3747/co.19.1078.

34.

A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer.

Cristofanilli M, Johnston SR, Manikhas A, Gomez HL, Gladkov O, Shao Z, Safina S, Blackwell KL, Alvarez RH, Rubin SD, Ranganathan S, Redhu S, Trudeau ME.

Breast Cancer Res Treat. 2013 Jan;137(2):471-82. doi: 10.1007/s10549-012-2369-x. Epub 2012 Dec 13.

35.

Health Canada/BIOTECanada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa, Canada, 14 May 2012.

Kay J, Feagan BG, Guirguis MS, Keystone EC, Klein AV, Lubiniecki AS, Mould DR, Nyarko KA, Ridgway AA, Trudeau ME, Wang J.

Biologicals. 2012 Nov;40(6):517-27. doi: 10.1016/j.biologicals.2012.09.010. Epub 2012 Oct 17.

36.

International variability in the reimbursement of cancer drugs by publically funded drug programs.

Cheema PK, Gavura S, Migus M, Godman B, Yeung L, Trudeau ME.

Curr Oncol. 2012 Jun;19(3):e165-76. doi: 10.3747/co.19.946.

37.

Insulin- and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations.

Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Taylor SK, Hood N.

J Clin Oncol. 2012 Jan 10;30(2):164-71. doi: 10.1200/JCO.2011.36.2723. Epub 2011 Dec 12.

PMID:
22162568
38.

Stage at diagnosis and comorbidity influence breast cancer survival in First Nations women in Ontario, Canada.

Sheppard AJ, Chiarelli AM, Marrett LD, Nishri ED, Trudeau ME.

Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2160-7. doi: 10.1158/1055-9965.EPI-11-0459. Epub 2011 Jul 29.

39.

Detection of later stage breast cancer in First Nations women in Ontario, Canada.

Sheppard AJ, Chiarelli AM, Marrett LD, Mirea L, Nishri ED, Trudeau ME; Aboriginal Breast Cancer Study Group.

Can J Public Health. 2010 Jan-Feb;101(1):101-5.

PMID:
20364549
40.

Cell phone cardiopulmonary resuscitation: audio instructions when needed by lay rescuers: a randomized, controlled trial.

Merchant RM, Abella BS, Abotsi EJ, Smith TM, Long JA, Trudeau ME, Leary M, Groeneveld PW, Becker LB, Asch DA.

Ann Emerg Med. 2010 Jun;55(6):538-543.e1. doi: 10.1016/j.annemergmed.2010.01.020. Epub 2010 Mar 4.

PMID:
20202719
41.

Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well tolerated.

Leyland-Jones B, Colomer R, Trudeau ME, Wardley A, Latreille J, Cameron D, Cubedo R, Al-Sakaff N, Feyereislova A, Catalani O, Fukushima Y, Brewster M, Cortés J.

J Clin Oncol. 2010 Feb 20;28(6):960-6. doi: 10.1200/JCO.2009.23.1910. Epub 2009 Dec 21.

PMID:
20026806
42.

Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response.

Wong NS, Buckman RA, Clemons M, Verma S, Dent S, Trudeau ME, Roche K, Ebos J, Kerbel R, Deboer GE, Sutherland DJ, Emmenegger U, Slingerland J, Gardner S, Pritchard KI.

J Clin Oncol. 2010 Feb 10;28(5):723-30. doi: 10.1200/JCO.2009.24.0143. Epub 2009 Dec 21.

PMID:
20026801
43.

Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.

Trudeau ME, Clemons MJ, Provencher L, Panasci L, Yelle L, Rayson D, Latreille J, Vandenberg T, Goel R, Zibdawi L, Rahim Y, Pouliot JF.

J Clin Oncol. 2009 Dec 10;27(35):5906-10. doi: 10.1200/JCO.2009.22.7504. Epub 2009 Oct 26.

PMID:
19858391
44.

Association of low tumor RNA integrity with response to chemotherapy in breast cancer patients.

Parissenti AM, Chapman JA, Kahn HJ, Guo B, Han L, O'Brien P, Clemons MP, Jong R, Dent R, Fitzgerald B, Pritchard KI, Shepherd LE, Trudeau ME.

Breast Cancer Res Treat. 2010 Jan;119(2):347-56. doi: 10.1007/s10549-009-0531-x.

PMID:
19771508
45.

A framework for the organization and delivery of systemic treatment.

Vandenberg T, Coakley N, Nayler J, Degrasse C, Green E, Mackay JA, McLennan C, Smith A, Wilcock L, Trudeau ME.

Curr Oncol. 2009 Jan;16(1):4-15.

46.

High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome.

Goodwin PJ, Ennis M, Bahl M, Fantus IG, Pritchard KI, Trudeau ME, Koo J, Hood N.

Breast Cancer Res Treat. 2009 Apr;114(3):517-25. doi: 10.1007/s10549-008-0019-0. Epub 2008 Apr 25.

PMID:
18437560
47.

Biological significance of occult micrometastases in histologically negative axillary lymph nodes in breast cancer patients using the recent American Joint Committee on Cancer breast cancer staging system.

Kahn HJ, Hanna WM, Chapman JA, Trudeau ME, Lickley HL, Mobbs BG, Murray D, Pritchard KI, Sawka CA, McCready DR, Marks A.

Breast J. 2006 Jul-Aug;12(4):294-301.

PMID:
16848838
48.

Stable isotopic analysis of atmospheric methane by infrared spectroscopy by use of diode laser difference-frequency generation.

Trudeau ME, Chen P, Garcia Gde A, Hollberg LW, Tans PP.

Appl Opt. 2006 Jun 10;45(17):4136-41.

PMID:
16761056
49.

Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG).

Trudeau ME, Crump M, Charpentier D, Yelle L, Bordeleau L, Matthews S, Eisenhauer E.

Ann Oncol. 2006 Jun;17(6):952-6. Epub 2006 Mar 24.

50.

Prognostic significance of circulating tumour cells enumerated after filtration enrichment in early and metastatic breast cancer patients.

Wong NS, Kahn HJ, Zhang L, Oldfield S, Yang LY, Marks A, Trudeau ME.

Breast Cancer Res Treat. 2006 Sep;99(1):63-9. Epub 2006 Mar 16.

PMID:
16541316

Supplemental Content

Loading ...
Support Center